International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease od Williamson, K, Lytvyak, E, De Krijger, M, Trivedi, P, Estes, D, Yu, L, Pratt, D, De Vries, A, Daretti, L, Liu, C, Bowlus, C, Marschall, H, Montano-Loza, A, Chapman, R, Van Der Woude, C, Marzioni, M, Keshav, S, Ponsioen, C, Hirschfield, G, Levy, C

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases od Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C